This week’s collection of the latest dermatologic studies includes social determinants of health in HS, JNJ-77242113 for moderate to severe plaque psoriasis, sonidegib for locally advanced and metastatic BCC, and pembrolizumab in combination with chemoradiotherapy for locally advanced HNSCC.
Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.
Our May issue of Dermatology Times spotlights melanoma/skin cancer awareness and more.
Earlier this week, we shared our fourth and final Rosacea Awareness Month quiz. Review the answers and your responses below.
May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life, and well-being.
A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.
The new research will compare eblasakimab to dupilumab and lebrikizumab.
This recap of skin cancer innovations accompanies the cover story of our May publication.
A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.
While 84% of commercials targeted female consumers and 77% utilized celebrity influence, less than half mentioned specific ingredients in skin lightening products.
These challenges may exacerbate racial inequities in care access and quality, according to a new study.
Adalimumab-adbm is now approved for use in various indications, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa.
Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.
Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.
Learn more about the in-depth topics covered in the April 2024 print issue of Dermatology Times.
Review Dermatology Times' coverage of Rosacea Awareness Month.
Dermatology Times is looking back on the top stories in dermatology from the month of April.
A decision from the FDA is expected in the second half of 2024.
Dermatology Times is recapping our top expert interviews from the month of April.
López-Ferrer discussed how to achieve well-being for patients with psoriasis and Koscielny discussed the unique topics of the Skin Academy.
A study revealed that patients with actinic keratosis reported feeling more pain during red light PDT compared to simulated daylight PDT.
A study found that in addition, recovery time was both quick and yielded minimal symptoms.
The FDA’s PDUFA date is expected in quarter 4 of 2024.
Click here to read more and answer our quiz questions in recognition of Rosacea Awareness Month.
Keep up with the latest headlines in dermatology from the past week, including the appointment of All Detergent's first chief dermatology advisor, Incyte's acquisition of Escient Pharmaceuticals, and more.
ICYMI, this week we had news about a study of upadacitinib versus dupilumab in atopic dermatitis, the European Union's approval of bimekizumab for HS, and more.
Mona Shahriari, MD, and a plaque psoriasis patient provide insights into the mechanism of action and benefits of tapinarof cream 1% as a nonsteroidal topical.
Study findings suggest OCT's effectiveness in accurately diagnosing and mapping BCC, with a high predictive capability for Mohs surgery requirements.
Skin cancer risk classification lacks reliability for darker skin tones and fails in evaluating cutaneous medical conditions or cosmetic interventions, according to creators of the scale.
Earlier this week, we shared our third Rosacea Awareness Month quiz. Review the answers and your responses below.
